Program
lenvatinib
Also written as “Lenvatinib”, “E7080” and “HOPE”.
Its studies are mostly in Carcinoma, Hepatocellular · Melanoma · Thyroid Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 4 companies.
Drug pageLenvatinib: every studyAll 431 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 511 open or running | phase 4since Jun 19, 2018 | Jul 15, 2005 | none ahead |
| Merck | 261 open or running | phase 3since Jan 22, 2019 | Aug 3, 2016 | Oct 22, 2027phase 2 · NCT02861573 |
| AGO Researchits history only | 11 open or running | phase 2since May 11, 2023 | May 11, 2023 | Oct 30, 2027phase 2 · NCT05903833 |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 1since Oct 4, 2021 | Oct 4, 2021 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical, PharmaBio Development and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Aug 3, 2016.
- Dec 12, 2019Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT04199104 · 511 enrolled · United States, Australia, Brazil and more
- Jan 27, 2020Phase 3 study in Carcinoma, HepatocellularNCT04246177 · 480 enrolled · United States, Australia, Brazil and more
- Mar 9, 20202 phase 2 studies in MelanomaNCT04305054, NCT04305041
- Jun 9, 20202 phase 2 studiesNCT04428151, NCT04447755
- Dec 4, 20202 phase 3 studiesNCT04662710, NCT04676412
- Jan 7, 2021Phase 2 study in Carcinoma, Renal CellNCT04704219 · 160 enrolled · United States, Australia, Canada and more
- Jan 19, 2021Phase 3 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT04716933 · 201 enrolled · China
- Feb 26, 2021Phase 3 study in Colorectal NeoplasmsNCT04776148 · 563 enrolled · United States, Argentina, Australia and more
- Apr 26, 2021Phase 3 study in Endometrial NeoplasmsNCT04865289 · 130 enrolled · China
- May 12, 2021Phase 3 study in MelanomaNCT04889118 · 131 enrolled · China
- Jun 9, 2021Phase 2 study in Small Cell Lung CarcinomaNCT04924101 · 122 enrolled · United States, Austria, Canada and more
- Jun 29, 2021Phase 3 study in Esophageal Squamous Cell CarcinomaNCT04949256 · 863 enrolled · United States, Argentina, Canada and more
- Aug 29, 2022Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT05523323 · 112 enrolled · China
- Nov 18, 2026Phase 2 study terminatedStudy stoppedNCT04428151 · “Business Reasons”
Ahead
- Oct 22, 2027Primary completion: phase 2 study in Metastatic Castration-Resistant Prostate CancerNCT02861573
TargetBeta
“A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase ”NCIt, by rule
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
Studies
All 26 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05523323Squamous Cell Carcinoma of Head and Neck · China | 3 | Completed | Aug 25, 2023 | 112 |
| NCT04949256Esophageal Squamous Cell Carcinoma · United States, Argentina, Canada and more | 3 | Terminated | May 8, 2025 | 863 |
| NCT04924101Small Cell Lung Carcinoma · United States, Austria, Canada and more | 2 | Completed | Jun 23, 2025 | 122 |
| NCT04889118Melanoma · China | 3 | Completed | Jan 18, 2023 | 131 |
| NCT04865289Endometrial Neoplasms · China | 3 | Completed | Oct 2, 2023 | 130 |
| NCT04776148Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sep 27, 2024 | 563 |
| NCT04716933Parkinson Disease 4, Autosomal Dominant Lewy Body · China | 3 | Completed | Aug 11, 2023 | 201 |
| NCT04704219Carcinoma, Renal Cell · United States, Australia, Canada and more | 2 | Completed | Jan 27, 2025 | 160 |
| NCT04676412Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | May 19, 2021 | 107 |
| NCT04662710Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more | 3 | Completed | Oct 29, 2024 | 895 |
| NCT04447755Recurrence · United States, Argentina, Australia and more | 2 | Completed | Sep 16, 2022 | 127 |
| NCT04428151Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more | 2 | Terminated | May 31, 2024 | 408 |
| NCT04305054Melanoma · United States, Argentina, Australia and more | 2 | Completed | May 18, 2026 | 335 |
| NCT04305041Melanoma · United States, Australia, France and more | 2 | Completed | Aug 25, 2025 | 100 |
| NCT04246177Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Terminated | Aug 19, 2025 | 480 |
| NCT04199104Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more | 3 | Completed | May 30, 2023 | 511 |
| NCT03976375Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Aug 11, 2023 | 422 |
| NCT03898180Carcinoma, Transitional Cell · United States, Argentina, Australia and more | 3 | Completed | Jul 26, 2021 | 505 |
| NCT03884101Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Oct 2, 2023 | 842 |
| NCT03829332Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 3 | Completed | May 19, 2021 | 623 |
| NCT03829319Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more | 3 | Completed | Aug 11, 2023 | 761 |
| NCT03820986Melanoma · United States, Australia, Austria and more | 3 | Completed | Jan 18, 2023 | 674 |
| NCT03797326Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Oct 28, 2024 | 611 |
| NCT03776136Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more | 2 | Completed | Oct 11, 2023 | 103 |
| NCT03516981Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more | 2 | Completed | Jun 13, 2025 | 245 |
| NCT02861573Metastatic Castration-Resistant Prostate Cancer | 2 | Active, not recruiting | Oct 22, 2027 | 1,200 |
How it is read
Names in the registry
- “Lenvatinib”, 72 entries
- “lenvatinib”, 7 entries
- “E7080”, 6 entries
- “HOPE”, 2 entries
- “E7080 capsule”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 10 studies
- Melanoma, 7 studies
- Thyroid Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Carcinoma, Renal Cell, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.